ABOUT
Who is GAH
Golden Age Health (GAH) is a pharmaceutical company specializing in the commercialization of innovative rare and specialty disease treatments, with a focus on China, Asia and Middle-East.
Leveraging a team of global pharma veterans and deep local expertise, GAH addresses the significant gap in patient access by bringing proven therapies to Chinese patients and beyond.
The company offers flexible collaboration models and comprehensive end-to-end commercialization services, including regulatory support, market access, patient engagement, and real-world evidence generation in China and other Asian and Middle Eastern markets.
GAH’s mission is to help global innovators launch rare-disease medicines in China, Asia and the Middle-East — cutting time-to-patient, lowering launch risk for innovators and creating sustainable value for payers and investors.
“My decades of launching breakthrough therapies —from Spinraza® to Keytruda® — have taught me a simple truth: science only fulfils its promise when patients can reach it. Golden Age Health exists to collapse that distance. Together with our partners we will turn access from a slogan into a measurable outcome—months, not years — for every family we serve.”
— Michel Vounatsos, Co-founder & Executive Chairman
RARE DISEASES
Rare Diseases In Numbers
Rare diseases are distinct from other diseases and characterized by high unmet need from a small patient pools. We are here to close the gap in under-served markets.
of rare diseases are life threatening. High unmet need and debilitating
Source: Rare Disease Int'l
85%
rare diseases identified worldwide. Only 5% have an approved treatment
Source: IQVIA
7'000
people affected globally, 3x more than all cancers combined.
Source: IQVIA
400m
rare disease treatments available in China vs Western Markets
Source: ISPOR
1 of 5
TEAM
Meet our team
Team led by former CEO of Biogen and regional presidents of Biogen and MSD who respectively led Asia’s hallmark Spinraza® and Keytruda® launches. We bring cross-functional depth in regulatory, market-access, real-world evidence combined with local presence in China and Middle-East. With 25+ rare and specialty disease launches, we have cut time-to-patient by up to 40% in underserved regions.
Michel Vounatsos
Co-founder & Executive Chairman
Former CEO of Biogen
Yossi BenAmram
Co-founder & Chief Strategy Officer
Former President Europe, MEA, Russia at MSD
Francis Wan
Co-founder &
CEO
Former Head of APAC at Biogen delivering Spinraza launch
Reda Rebib
Business development & Finance
Former healthcare investor at EQT Partners
Chao (Brook) Wu
Affiliated Regional Partners
China
Yacine Hadjiat
Affiliated Regional Partners
MEA
Murali
Parthasarathy
Affiliated Regional Partners
US & India
Jose
Bastos
Affiliated Regional Partners
Latin America
APPROACH
How we work
Partnering with Golden Age Health means benefiting from proven expertise in launching rare and specialty disease treatments, especially in complex markets like China and Asia. We prioritize solving real patient journey challenges, ensuring accessible and affordable therapies tailored to unmet medical needs. Our global team navigates regulatory and market complexities with a patient-centric approach, leveraging deep local knowledge for compliant, successful launches. Expect a focused, innovative partner dedicated to commercializing rare and specialty disease solutions where they matter most.
OUR EDGE
What sets us apart
01
Rare Disease Launch Experience
Our team has done the most successful rare disease launches in China and Asia including Spinraza®, Tysabri® and Keytruda®.
02
End to End Commercialisation
From dossier preparation to supply-chain management, omnichannel medical engagement, and real-world evidence generation, we own the entire value chain.
03
Flexible deal structures
Up-front + milestone, distribution & promotion, profit-share, or JV—our models fit partners of every size.
04
Data-drive execution
Real-world data and AI-powered analytics drive precise patient-finding, adherence programs, and pricing strategies.
05
Pan-regional reach
One platform, three regions: mainland China + Hainan Pilot Zone, key ASEAN markets, and leading Gulf Cooperation Council (GCC) countries.
PRODUCTS
Our portfolio
Raxone
Supporting Chiesi Farmaceutici to expand Raxone access to China
Gene Therapy
Gene Therapy in rare ophthalmology. To be announced in July
Your Product?
NEWS
News and Press releases
Golden Age Health Appoints Francis Wan as Chief Executive Officer Effective June 1st, 2024
May 21, 2024
Golden Age Health (GAH) to participate in the JPM Healthcare Conference in San Francisco, January 8-11, 2024
January 8, 2024